Tyrvaya (Varenicline Tartrate) Patent Expiration, LOE Window & CMS Spending
Tyrvaya (Varenicline Tartrate) by Oyster Point: FDA Orange Book LOE 2035-10-19, 20 AB generics, $79.1M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Oyster Point |
| FDA Application & Pathway | N213978 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2035-10-19 |
| Orange Book Patents (*PED Extensions) | 12 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 20 |
| 2024 CMS Total Public Spend | $79.1M |
| 2024 Medicare Part D Spend | $71.7M |
| 2024 Medicaid Spend | $7.4M |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |